PR status is a more decisive factor in efficacy of adding pertuzumab into neoadjuvant therapy for HER2-positive and lymph node-positive breast cancer than ER status: a real-world retrospective study in China - Liu, Xiaoyu; Liu, Zhaoyun; Li, Chao; Song, Xiang; Wang, Xinzhao; Li, Sumei; Yu, Zhiyong (World journal of surgical oncology, 2023)
Keywords: Breast cancer; Cancer therapies; Care and treatment; Chemotherapy; Dosage and administration; Effectiveness; ErbB-2 protein; Estrogen receptors; Estrogens; Evaluation; HER2-positive breast cancer; Immunotherapy; Lymph nodes; Lymphatic system; Medical prognosis; Metastases; Metastasis; Methods; Monoclonal antibodies; Neoadjuvant therapy; Pathological complete response; Patients; Pertuzumab; Progesterone; Progesterone receptor; Receptors; Statistical analysis; Surgery; Targeted cancer therapy; Therapy; Trastuzumab; Tumors; China